Back to Search
Start Over
Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.
- Source :
- JGIM: Journal of General Internal Medicine; Jul2020, Vol. 35 Issue 7, p2025-2034, 10p, 1 Diagram, 3 Charts, 2 Graphs
- Publication Year :
- 2020
-
Abstract
- Background: Cure from chronic hepatitis C virus (HCV) infection is readily achievable with direct-acting antivirals (DAA), but little is known about optimal management after treatment. Weight gained after DAA treatment may mitigate benefits or increase risk for liver disease progression. As the single largest sample of HCV-infected individuals receiving DAA treatment in the United States, the Veterans Affairs (VA) Birth Cohort is an ideal setting to assess weight gain after DAA treatment. Methods: We performed a prospective study of patients dispensed DAA therapy from January 2014 to June 2015. Weight change was calculated as the difference in weight from sustained virologic response (SVR) determination to 2 years later. Demographic, weight, height, prescription, laboratory, and diagnosis code data were used for covariate definitions. We used multiple logistic regression to assess the association between candidate predictors and excess weight gain (≥ 10 lbs) after 2 years. Results: Among 11,469 patients, 78.0% of patients were already overweight or obese at treatment initiation. Overall, SVR was achieved in 97.0% of patients. After 2 years, 52.6% of patients gained weight and 19.8% gained excess weight. In those with SVR, weight gain was as high as 38.2 lbs, with the top 10% gaining ≥ 16.5 lbs. Only 1% of those with obesity at treatment initiation normalized their weight class after 2 years. Significant predictors of post-SVR weight gain were SVR achievement, lower age, high FIB-4 score, cirrhosis, and weight class at treatment initiation. Conclusion: Weight gain is common after DAA treatment, even among those who are overweight or obese prior to treatment. Major predictors include age, baseline weight, alcohol, cirrhosis, and SVR. Everyone receiving DAAs should be counseled against weight gain with a particular emphasis among those at higher risk. [ABSTRACT FROM AUTHOR]
- Subjects :
- WEIGHT gain
HEPATITIS C
CHRONIC hepatitis C
HEPATITIS C virus
ANTIVIRAL agents
Subjects
Details
- Language :
- English
- ISSN :
- 08848734
- Volume :
- 35
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- JGIM: Journal of General Internal Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 144498444
- Full Text :
- https://doi.org/10.1007/s11606-020-05782-6